Hugel to Develop Next-generation Type E Botulinum Toxin Product

May 9, 2024
Botox glabellar injection (drawn)

Hugel has started its development of new botulinum toxin products using a botulinum toxin type that has a faster onset and shorter duration of effect, the aesthetics firm said.

According to Hugel, botulinum neurotoxins that are currently used for therapeutic and cosmetic applications have been botulinum neurotoxin type A and B. The onset of action of botulinum toxin A, which is most widely used for cosmetic applications, ranges from three to seven days, while its therapeutic effect usually lasts around three six months.

On the other hand, the onset of botulinum neurotoxin type E’s clinical effect is within 24 hours, with a duration ranging from two to four weeks.

Read more at The Korea Herald >>

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • AMA Urges HHS to Withdraw Proposal Expanding Access to Certain Unapproved Peptides
    • Health Canada Warns Against Unauthorized Peptides After Bacteria Found in Seized Products
    • FDA Authorizes Clinical Trials Evaluating Lynch Regenerative Medicine’s rhPDGF-BB for Facial Skin Quality and Infraorbital Hollows
    • Hims & Hers Launches Peptides+ for Men
    • Alpha Aesthetics Partners Launches Clinical Education for Platform Practices